Eris Lifesciences Ltd

Eris Lifesciences Limited has announced a Board of Directors meeting scheduled for Monday, October 26, 2026. The primary agenda is to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended September 30, 2026. The company has also informed that the trading window for designated persons and their relatives has been closed from October 01, 2026, and will reopen 48 hours after the declaration of these financial results, in compliance with SEBI regulations.

Eris Lifesciences Ltd has announced that its Board of Directors will convene on October 26, 2026. The primary agenda item for this meeting is to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended September 30, 2026. The company also confirmed that the trading window, which closed on October 1, 2026, will remain shut until 48 hours after the financial results are declared, in compliance with SEBI regulations.

Eris Lifesciences Ltd has announced the resignation of Mr. Krishnakumar Vaidyanathan from his positions as Executive Director and Chief Operating Officer (COO). The resignation is effective from the close of business hours on September 30, 2026. Mr. Vaidyanathan is leaving to pursue professional opportunities outside the company. He expressed gratitude to the company's directors for their support during his tenure and requested that his resignation be accepted, with the notice period waived and necessary formalities completed.

Eris Lifesciences Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from October 01, 2026, and will reopen 48 hours after the declaration of the company's unaudited financial results for the quarter and half-year ending September 30, 2026. All concerned individuals are advised against trading in the company's securities during this period. This notice is independent of any other trading window closure announcements.

Eris Lifesciences Ltd has announced the allotment of 1,55,264 equity shares on September 22, 2026, following the exercise of options under its ESOP Scheme. The shares were allotted from different grant years: 66,422 shares from the 2022 grant at ₹557.24 each, 57,239 shares from the 2023 grant at ₹510.32 each, and 31,603 shares from the 2024 grant at ₹728.16 each. Consequently, the company's paid-up share capital has increased from ₹13,85,83,305 to ₹13,87,38,569.

Eris Lifesciences Ltd has announced the appointment of Mr. Akhil Awasthi as an Additional Director (Non-executive, Independent) to its Board of Directors. The appointment, approved via a circular resolution dated September 21, 2026, is effective from September 26, 2026, for a term of five years, subject to shareholder approval. Mr. Awasthi brings over three decades of experience in private equity, investment management, healthcare, and corporate governance, having held senior roles at Tata Capital Growth Fund and Baring Private Equity Partners (India) Ltd. He is not related to any existing director and is not debarred from holding a directorship.

Eris Lifesciences Ltd announced that Mr. Krishnakumar Vaidyanathan has resigned from his position as Executive Director & Chief Operating Officer (COO). He is stepping down to pursue external professional opportunities. The resignation has been accepted by the Chairman, and he will be relieved of his duties effective September 30, 2026. The company expressed gratitude for his contributions.

Eris Lifesciences Limited has issued a clarification regarding recent publications from InvestyWise News, dealroom.co, and others that may have misrepresented the company's loan value. The company directs readers to refer to its official disclosures disseminated through the exchange for accurate information. This statement serves to verify and correct any potential misinformation concerning the company's financial dealings, emphasizing reliance on official exchange filings for investment decisions.

Eris Lifesciences Ltd has entered into an agreement to avail a term loan of ₹45,00,00,000/- (Rupees Forty Five Crores Only) from Axis Bank Limited. The loan is intended to meet other liabilities. The company stated that this is a routine financial adjustment and will not impact the expected Net Debt figure at the end of the quarter. The loan agreement was executed on September 09, 2026, and Axis Bank will have a charge on the company's brands as security. This transaction does not involve related parties.

Eris Lifesciences Ltd has announced its 20th Annual General Meeting (AGM) scheduled for Friday, September 25, 2026, at 11:00 AM IST, to be conducted via Video Conferencing (VC). The company has also released its Annual Report for the Financial Year 2025-26. Both the Annual Report and the Notice of AGM are available on the company's website. The report includes sections on corporate overview, financial highlights, business segments, R&D, manufacturing, and ESG initiatives.